{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:34Z","timestamp":1793755654817,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102028","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:41:39Z","timestamp":1790034099000},"page":"102028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Magnitude of portal pressure reduction and clinical outcomes in randomized trials"],"prefix":"10.1016","volume":"8","author":[{"given":"Matthew","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4532-4347","authenticated-orcid":false,"given":"Jarell","family":"Jie-Rae Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Veldhuijzen van Zanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-4797","authenticated-orcid":false,"given":"Shuen","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice Y.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-1183","authenticated-orcid":false,"given":"Yu Jun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-937X","authenticated-orcid":false,"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102028_bib1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.cgh.2023.03.019","article-title":"Update in the treatment of the complications of cirrhosis","volume":"21","author":"Abraldes","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102028_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib3","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","article-title":"Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis","volume":"18","author":"Turco","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102028_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2004.07.023","article-title":"The relationship between liver function and portal pressure: what comes first, the chicken or the egg?","volume":"42","author":"Triantos","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102028_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u201ctrial-level\u201d surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.102028_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.102028_bib8","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2026.102028_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib10","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/hep.32033","article-title":"Test-retest reliability and consistency of HVPG and impact on trial design: a study in 289 patients from 20 randomized controlled trials","volume":"74","author":"Bai","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhepr.2026.102028_bib12","series-title":"Cochrane Handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jhepr.2026.102028_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12072-019-09986-9","article-title":"Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial","volume":"13","author":"Kumar","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2026.102028_bib14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/liv.12172","article-title":"Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial","volume":"33","author":"Gupta","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102028_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102028_bib18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2026.102028_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.jhepr.2026.102028_bib21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/01621459.1994.10476871","article-title":"Simulation-extrapolation estimation in parametric measurement error models","volume":"89","author":"Cook","year":"1994","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jhepr.2026.102028_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jhepr.2026.102028_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jhepr.2026.102028_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJM198312223092502","article-title":"Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis","volume":"309","author":"Burroughs","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102028_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.1840060602","article-title":"Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial","volume":"6","author":"Villeneuve","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/0016-5085(87)90247-2","article-title":"Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo","volume":"93","author":"Pomier-Layrargues","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.1840130517","article-title":"Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group","volume":"13","author":"Conn","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0016-5085(90)91168-6","article-title":"Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage","volume":"99","author":"Groszmann","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/bmj.315.7119.1338","article-title":"Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage","volume":"315","author":"Jenkins","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2026.102028_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/jhep.2003.50032","article-title":"Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study","volume":"37","author":"Abecasis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102028_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2004.05.004","article-title":"A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis","volume":"127","author":"Merkel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102028_bib32","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102028_bib33","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00535-011-0449-z","article-title":"Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial","volume":"46","author":"Hidaka","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102028_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12072-012-9353-8","article-title":"Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial","volume":"7","author":"Sarin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2026.102028_bib35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/gutjnl-2016-311735","article-title":"Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial","volume":"66","author":"Bhardwaj","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102028_bib36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102028_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102028_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102028_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.102028_bib40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s12072-024-10687-1","article-title":"Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial","volume":"18","author":"Ranjan","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2026.102028_bib41","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1136\/gutjnl-2023-331181","article-title":"Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the \u201cCAVARLY TRIAL.\u201d","volume":"73","author":"Tevethia","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102028_bib42","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.14309\/ajg.0000000000003650","article-title":"Efficacy and Safety of carvedilol in cirrhosis patients with new-Onset Uncomplicated ascites without high-risk esophageal varices (CARVE-AS trial)","volume":"121","author":"Khajuria","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102028_bib43","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102028_bib44","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102028_bib45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:55:47Z","timestamp":1793753747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926002995"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102028","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnitude of portal pressure reduction and clinical outcomes in randomized trials","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102028"}}